Skip to main content
Erschienen in: International Ophthalmology 2/2019

16.01.2018 | Original Paper

Mitomycin C 0.02 and 0.002% efficacy in preventing haze after photorefractive keratectomy

verfasst von: L. M. Coelho, R. O. Sieiro

Erschienen in: International Ophthalmology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare MMC 0.002% efficacy in preventing haze after PRK in relation to MMC 0.02%.

Patients and methods

We conducted a prospective study with patients with myopia or myopic astigmatism undergoing PRK in the same conditions. After PRK, MMC was applied for 30 s in a concentration of 0.02% on the right eye (group 1) and 0.002% on the left eye (group 2). Age, gender, spherical equivalent and haze intensity (1, 3, 6 and 12 months postoperatively) were assessed. Haze was quantified at biomicroscopy (0–4 +). P < 0.05 was considered statistical significant.

Results

We evaluated 130 patients, 77 women and 53 men, with a mean age of 30.2 ± 9 years. The spherical equivalent was − 3.66 D in the group 1 and − 3.77 D in the group 2. In the 1st month after PRK, incidence of haze was 13.9% eyes in group 1 and 14.6% in group 2. In the 3rd month, incidence of haze was 50.0% eyes in group 1 and 48.5% in group 2 which presented with 3 +/4 + traces of haze. In the 12th month, incidence of haze was 7.7% eyes in group 1 and 5.4% in group 2. There was no correlation between haze and age (p = 0.279/0.333), gender (p = 0.345/0.367) or spherical equivalent (p = 0.100/0.054) in groups 1 and 2, respectively. There was no difference in haze between groups 1 and 2 (p = 0.56).

Conclusion

MMC 0.002% was effective in preventing haze after PRK. As MMC long-term safety has not been proved, we suggest its use in a lower concentration, in order to prevent potential complications.
Literatur
1.
Zurück zum Zitat Santhiago MR, Netto MV, Wilson SE (2012) Mitomycin C: biological effects and use in refractive surgery. Cornea 31(3):311–321CrossRefPubMed Santhiago MR, Netto MV, Wilson SE (2012) Mitomycin C: biological effects and use in refractive surgery. Cornea 31(3):311–321CrossRefPubMed
2.
Zurück zum Zitat Netto MV et al (2006) Effect of prophylactic and therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze, and long-term keratocyte density in rabbits. J Refract Surg 22:562–574CrossRefPubMedPubMedCentral Netto MV et al (2006) Effect of prophylactic and therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze, and long-term keratocyte density in rabbits. J Refract Surg 22:562–574CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Naderi M, Ahmadi M, Jadidi K, Alishiri A, Rafizadeh P (2010) Comparison of standard and low dose mitomycin C in the prevention of corneal haze following photorefractive keratectomy. Iran J Ophthalmol 22(3):13–16 Naderi M, Ahmadi M, Jadidi K, Alishiri A, Rafizadeh P (2010) Comparison of standard and low dose mitomycin C in the prevention of corneal haze following photorefractive keratectomy. Iran J Ophthalmol 22(3):13–16
4.
Zurück zum Zitat Teus MA, Benito-Llopis L, Alió JL (2009) Mitomycin C in corneal refractive surgery. Surv Ophthalmol 54:487–502CrossRefPubMed Teus MA, Benito-Llopis L, Alió JL (2009) Mitomycin C in corneal refractive surgery. Surv Ophthalmol 54:487–502CrossRefPubMed
5.
Zurück zum Zitat Netto MV, Mohan RR, Sinha S et al (2006) Stromal haze, myofibroblasts, and surface irregularity after PRK. Exp Eye Res 82:788–797CrossRefPubMed Netto MV, Mohan RR, Sinha S et al (2006) Stromal haze, myofibroblasts, and surface irregularity after PRK. Exp Eye Res 82:788–797CrossRefPubMed
6.
Zurück zum Zitat Diakonis VF et al (2014) Contralateral-eye study of surface refractive treatments: clinical and confocal microscopy evaluation. J Cataract Refract Surg 40:224–231CrossRefPubMed Diakonis VF et al (2014) Contralateral-eye study of surface refractive treatments: clinical and confocal microscopy evaluation. J Cataract Refract Surg 40:224–231CrossRefPubMed
7.
Zurück zum Zitat Lacayo GO III, Majmudar PA (2005) How and when to use mitomycin-C in refractive surgery. Curr Opin Ophthalmol 16:256–259CrossRefPubMed Lacayo GO III, Majmudar PA (2005) How and when to use mitomycin-C in refractive surgery. Curr Opin Ophthalmol 16:256–259CrossRefPubMed
8.
Zurück zum Zitat Thornton I, Puri A, Xu M, Krueger RR (2007) Low-dose mitomycin C as a prophylaxis for corneal haze in myopic surface ablation. Am J Ophthalmol 144:673–681CrossRefPubMed Thornton I, Puri A, Xu M, Krueger RR (2007) Low-dose mitomycin C as a prophylaxis for corneal haze in myopic surface ablation. Am J Ophthalmol 144:673–681CrossRefPubMed
9.
Zurück zum Zitat Majmudar PA et al (2000) Topical mitomycin-C for subepithelial fibrosis after refractive corneal surgery. Ophthalmology 107:89–94CrossRefPubMed Majmudar PA et al (2000) Topical mitomycin-C for subepithelial fibrosis after refractive corneal surgery. Ophthalmology 107:89–94CrossRefPubMed
10.
Zurück zum Zitat Sia RK, Ryan DS, Edwards JD, Stutzman RD, Bower KS (2014) The U.S. army surface ablation study: comparison of PRK, MMC-PRK, and LASEK in moderate to high myopia. J Refract Surg 30(4):256–264CrossRefPubMed Sia RK, Ryan DS, Edwards JD, Stutzman RD, Bower KS (2014) The U.S. army surface ablation study: comparison of PRK, MMC-PRK, and LASEK in moderate to high myopia. J Refract Surg 30(4):256–264CrossRefPubMed
11.
Zurück zum Zitat Virasch VV, Majmudar PA, Epstein RJ et al (2010) Reduced application time for prophylactic mitomycin C in photorefractive keratectomy. Ophthalmology 117:885–889CrossRefPubMed Virasch VV, Majmudar PA, Epstein RJ et al (2010) Reduced application time for prophylactic mitomycin C in photorefractive keratectomy. Ophthalmology 117:885–889CrossRefPubMed
12.
Zurück zum Zitat Hofmeister EM, Bishop FM, Kaupp SE, Schallhorn SC (2013) Randomized dose-response analysis of mitomycin-C to prevent haze after photorefractive keratectomy for high myopia. J Cataract Refract Surg 39:1358–1365CrossRefPubMed Hofmeister EM, Bishop FM, Kaupp SE, Schallhorn SC (2013) Randomized dose-response analysis of mitomycin-C to prevent haze after photorefractive keratectomy for high myopia. J Cataract Refract Surg 39:1358–1365CrossRefPubMed
13.
Zurück zum Zitat Gambato C, Ghirlando A, Moretto E, Busato F, Midena E (2005) Mitomycin C modulation of corneal wound healing after photorefractive keratectomy in highly myopic eyes. Ophthalmology 112:208–219CrossRefPubMed Gambato C, Ghirlando A, Moretto E, Busato F, Midena E (2005) Mitomycin C modulation of corneal wound healing after photorefractive keratectomy in highly myopic eyes. Ophthalmology 112:208–219CrossRefPubMed
14.
Zurück zum Zitat Crawford C et al (2013) Systemic absorption of mitomycin-C when used in refractive surgery. J Cataract Refract Surg 39:193–196CrossRefPubMed Crawford C et al (2013) Systemic absorption of mitomycin-C when used in refractive surgery. J Cataract Refract Surg 39:193–196CrossRefPubMed
15.
Zurück zum Zitat Song JS, Kim JH, Yang M, Sul D, Kim HM (2007) Mitomycin C concentration in cornea and aqueous humor and apoptosis in the stroma after topical mitomycin-C application. Effects of mitomycin-C application time and concentration. Cornea 26:461–467CrossRefPubMed Song JS, Kim JH, Yang M, Sul D, Kim HM (2007) Mitomycin C concentration in cornea and aqueous humor and apoptosis in the stroma after topical mitomycin-C application. Effects of mitomycin-C application time and concentration. Cornea 26:461–467CrossRefPubMed
16.
Zurück zum Zitat Stojanovic A, Nitter TA (2001) Correlation between ultraviolet radiation level and the incidence of late-onset corneal haze after photorefractive keratectomy. J Cataract Refract Surg 27:404–410CrossRefPubMed Stojanovic A, Nitter TA (2001) Correlation between ultraviolet radiation level and the incidence of late-onset corneal haze after photorefractive keratectomy. J Cataract Refract Surg 27:404–410CrossRefPubMed
Metadaten
Titel
Mitomycin C 0.02 and 0.002% efficacy in preventing haze after photorefractive keratectomy
verfasst von
L. M. Coelho
R. O. Sieiro
Publikationsdatum
16.01.2018
Verlag
Springer Netherlands
Erschienen in
International Ophthalmology / Ausgabe 2/2019
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-017-0817-7

Weitere Artikel der Ausgabe 2/2019

International Ophthalmology 2/2019 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Die überschießende Wundheilung in der filtrierenden Glaukomchirurgie ist ein zentraler Faktor für ein operatives Versagen. Nach der Einführung der Trabekulektomie in den 1960er-Jahren wurden viele Faktoren erkannt, die mit einer vermehrten …

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.